Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 1/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 1.00 |
| ▸ | PARP15 | Q460N3 | 1/20 | 1.00 |
| ▸ | PARP14 | Q460N5 | 1/20 | 1.00 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 1.00 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 1.00 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 1.00 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 1.00 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 1.00 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olaparib SCHEMBL29352148 | 1.00 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| Olaparib SCHEMBL29392087 | 1.00 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| Olaparib SCHEMBL28083947 | 0.96 | PARP1 (0.93) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22852727 | 0.96 | PARP1 (0.98) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL28732627 | 0.95 | PARP1 (0.91) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22829780 | 0.94 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL19569971 | 0.92 | PARP1 (0.90) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL22852988 | 0.91 | PARP1 (0.89) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL9280839 | 0.91 | PARP1 (0.83) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL15846235 | 0.91 | PARP1 (0.83) | PARP1TNKSADORA1CDK6PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 795 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178816-B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARMACEUTICALS LIMITED (GB) | 2024-12-31 | — | — | US | claimed |
| US-20240398796-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | ASTRAZENECA UK LIMITED (GB) | 2024-12-05 | — | — | US | claimed |
| US-20240382479-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | ASTRAZENECA UK LIMITED (GB) | 2024-11-21 | — | — | US | claimed |
| US-12144810-B1 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARMACEUTICALS LIMITED (GB) | 2024-11-19 | — | — | US | claimed |
| US-12048695-B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARMACEUTICALS LIMITED (GB) | 2024-07-30 | — | — | US | claimed |
| CN-118139624-A | Methods of treating breast cancer | 阿斯利康(瑞典)有限公司 | 2024-06-04 | — | — | CN | claimed |
| US-11975001-B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARMACEUTICALS LIMITED (GB) | 2024-05-07 | — | — | US | claimed |
| US-20230346780-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2023-11-02 | — | — | US | claimed |
| US-20230338372-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | ABBOTT GMBH & CO. KG (DE) | 2023-10-26 | — | — | US | claimed |
| EP-2346495-B2 | PHARMACEUTICAL FORMULATION 514 | KUDOS PHARM LTD (GB) | 2023-05-24 | — | — | EP | claimed |
| WO-2010082821-A1 | METHOD OF TREATING CANCER | ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM (NL) | 2010-07-22 | — | — | WO | claimed |
| US-20100098763-A1 | PHARMACEUTICAL FORMULATION 514 | ASTRAZENECA AB | 2010-04-22 | — | — | US | claimed |
| WO-2010041051-A1 | PHARMACEUTICAL FORMULATION 514 | ASTRAZENECA UK LIMITED (GB) | 2010-04-15 | — | — | WO | claimed |
| US-7692006-B2 | Phthalazinone derivatives | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | claimed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | claimed |
| WO-2009050469-A1 | 4- [3- (4-CYCLOPROPANECARBONYL-PIPERAZINE-I-CARBONYL) -4 -FLUORO-BENZYL] -2H-PHTHALAZ IN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-04-23 | — | — | WO | claimed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
| WO-2008020180-A2 | METHODS OF INCREASING THE SENSITIVITY OF CANCER CELLS TO DNA DAMAGE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11975001-B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-12144810-B1 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-12178816-B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-20240398796-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-12048695-B2 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885PARP3 4/4885 |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | PARP1 379/4885PARP2 387/4885PARP3 1682/4885 |
| US-20100098763-A1 | PHARMACEUTICAL FORMULATION 514 | CYP3A7, CYP3A43, CYP3A4 | PARP1 238/4885PARP2 242/4885PARP3 812/4885 |
| US-20230338372-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-20240382479-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
| US-20230346780-A1 | IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | FKBP2, FKBP1A, CPNE4 | PARP1 1065/4885PARP2 1171/4885PARP3 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.